BioTelemetry, Inc. (NASDAQ:BEAT) reported Q2 2017 earnings this Afternoon, coming in at $0.23 per share, beating Wall Street’s estimates of $0.21 per Share. Revenue for the quarter came in at $58.10 million missing the streets estimates of $58.39 million
Analyst Coverage For BioTelemetry, Inc. (NASDAQ:BEAT)
These are 5 Buy Ratings .
The current consensus rating for BioTelemetry, Inc. (NASDAQ:BEAT) is Buy (Score: 3.00) with a consensus target price of $39.50 , a potential (12.06% upside)Recent Insider Trading for BioTelemetry, Inc. (NASDAQ:BEAT)
- On 5/15/2017 Robert J. Rubin, Director, sold 15,000 with an average share price of $28.14 per share and the total transaction amounting to $422,100.00.
- On 3/20/2017 Fred Broadway, SVP, sold 3,429 with an average share price of $26.90 per share and the total transaction amounting to $92,240.10.
- On 2/27/2017 George Hrenko, SVP, sold 126,043 with an average share price of $25.95 per share and the total transaction amounting to $3,270,815.85.
- On 2/21/2017 Fred Broadway, SVP, sold 8,070 with an average share price of $24.81 per share and the total transaction amounting to $200,216.70.
- On 9/19/2016 George Hrenko, SVP, sold 1,061 with an average share price of $18.50 per share and the total transaction amounting to $19,628.50.
- On 9/13/2016 Heather C Getz, CFO, sold 5,866 with an average share price of $18.23 per share and the total transaction amounting to $106,937.18.
Recent Trading for BioTelemetry, Inc. (NASDAQ:BEAT) Shares of BioTelemetry, Inc. closed the previous trading session at 35.25 up +0.10 0.28% with 663,601 shares trading hands.